Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality October 17, 2025 – In the volatile world of biotechnology, ambitious price targets often fuel investor speculation and market buzz. However, for Turnstone Biologics Corp. (
NASDAQ: TSTN ), the notion of its stock reaching a $100 valuation stands in stark contrast to its current precarious financial and operational state. Despite the transformative
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health Is there a glimmer of hope for either of these underperforming healthcare companies?
Is Iovance Biotherapeutics Stock Your Ticket to Becoming a Millionaire? Investors have certainly seen explosive gains from shares of biopharma companies in similar situations.
Can This Beaten-Down Stock Bounce Back? This biotech company is innovative, but the market demands more than that.
If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today The company hasn't been popular among investors since winning its first FDA approval more than a year ago.
Why Iovance Biotherapeutics Stock Got Mashed on Monday The company announced a flotation of its common shares that is potentially quite dilutive.
Why Iovance Biotherapeutics Stock Was Climbing Today One and a half years after getting the nod from the U.S. Food and Drug Administration, its Amtagvi moves forward in a neighboring country.
Curious about the stocks that are showing activity after the closing bell on Monday? As the regular session of the US market concludes on Monday, let's get an insight into the after-hours session and identify the stocks leading the pack in terms of gains and losses.
3 Stocks That Could Turn $1,000 Into $5,000 by 2030 All three of these companies are entering a period of what could produce unparalleled top- and bottom-line growth.
Which stocks are moving before the opening bell on Friday? Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Iovance Biotherapeutics Declines 29% In Premarket Trading: Here's What's Happening Iovance stock fell over 29% pre-market after Q2 results, despite reporting a strong revenue jump led by Amtagvi sales.
Curious about the stocks that are showing activity after the closing bell on Thursday? Wondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
